Details of the Drug

General Information of Drug (ID: DMUB8WN)

Drug Name

Aerovant

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2a	[1]
------------------------------------------------------------------------------------

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 4 receptor alpha (IL4R)	TTDWHC3	IL4RA_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Asthma

ICD Disease Classification

CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 4 receptor alpha (IL4R)	DTT	IL4R	1.48E-08	0.76	3.74

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
2	Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009.